Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02. The firm earned $24.73 million during the quarter, compared to analysts' expectations of $29.43 million. Nektar Therapeutics had a negative net margin of 150.74% and a negative return on equity of 3,072.86%. The firm's revenue for the quarter was down 58.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.14) EPS. View Nektar Therapeutics' Earnings History.

8 equities research analysts have issued 1-year price targets for Nektar Therapeutics' shares. Their forecasts range from $23.00 to $31.00. On average, they anticipate Nektar Therapeutics' share price to reach $26.29 in the next twelve months. View Analyst Ratings for Nektar Therapeutics.

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

• 1. According to Zacks Investment Research, "Nektar reported wider than expected loss in fourth quarter 2016 with revenue missing estimates. The launches of its drugs Movantik and Adynovate have been on track with both the products performing impressively. Moreover, partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone plus royalties for Movantik under the license agreement with AstraZeneca, which will boost its financial position significantly. Nektar also has a deep and promising pipeline, with several updates lined up for the next several quarters. However, Nektar relies heavily on partners for revenues. Partnership-related setbacks may weigh heavily on the company, and disappointing products sales could have a significant impact on its financial results. The company’s shares outperformed the Zacks classified Medical-Drugs industry in the year so far." (3/27/2017)
• 2. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
• 3. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)
• 4. Aegis analysts commented, "NKTR-181 met its primary endpoint in the phase III Summit-07 trial - increase Price Target to $25. Yesterday morning, Netkar Therapeutics announced that NKTR-181 met its primary endpoint of mean change in weekly average numeric rating scale (NRS) pain score for the randomized, double-blind treatment period from the end of the open-label titration period (baseline) to week 12. Average pain scores measured at week 12 from baseline increased 1.46 for placebo vs. 0.92 for NKTR-181 (p=0.0019). We had not previously factored in revenue from NKTR-181 into our price target. As a result of the positive phase III results, we now include such revenue under partnering assumptions in the US and raise our price target from $21 to $24." (3/20/2017)

Some companies that are related to Nektar Therapeutics include Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), PAREXEL International Corporation (PRXL), Exact Sciences Corporation (EXAS), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE), INC Research Holdings (INCR), Intrexon Corporation (XON) and Ligand Pharmaceuticals Incorporated (LGND).

Nektar Therapeutics' management team includes the folowing people:

• Robert B. Chess, Independent Chairman of the Board
• Howard W. Robin, President, Chief Executive Officer, Director
• Gilbert M. Labrucherie J.D., Chief Financial Officer, Senior Vice President
• John L. Nicholson, Chief Operating Officer, Senior Vice President
• Jillian B. Thomsen, Senior Vice President - Finance, Chief Accounting Officer
• Stephen K. Doberstein Ph.D., Senior Vice President, Chief Scientific Officer
• Ivan Philip Gergel M.D., Senior Vice President - Drug Development & Chief Medical Officer
• Maninder Hora Ph.D., Senior Vice President - Pharmaceutical Development and Manufacturing Operations
• R. Scott Greer, Independent Director
• Joseph J. Krivulka, Independent Director

Nektar Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Harvey Capital Management Inc. (0.19%), Russell Investments Group Ltd. (0.09%), US Bancorp DE (0.06%), Louisiana State Employees Retirement System (0.04%), Rothschild Capital Partners LLC (0.04%) and Franklin Street Advisors Inc. NC (0.04%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Stephen K Doberstein and Susan Wang. View Institutional Ownership Trends for Nektar Therapeutics.

Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Capstone Asset Management Co., Shell Asset Management Co. and Bank of Montreal Can. Company insiders that have sold Nektar Therapeutics stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Nektar Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Capital Partners LLC, Russell Investments Group Ltd., State of Alaska Department of Revenue, Aperio Group LLC, Harvey Capital Management Inc., Municipal Employees Retirement System of Michigan, LS Investment Advisors LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Nektar Therapeutics.

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Nektar Therapeutics stock can currently be purchased for approximately $23.12.